Clinical trial
A Phase 1 Study of REGN6569, an Anti-GITR mAb, With Cemiplimab in Patients With Advanced Solid Tumor Malignancies
NCT04465487 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of REGN6569, an Anti-GITR mAb, With Cemiplimab in Patients With Advanced Solid Tumor Malignancies
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 5, 2020
- Completion date
- February 7, 2025
- Enrollment
- 38 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.